Get the latest Science News and Discoveries
Insilico Medicine completes patient enrollment in its Phase IIa Study in China investigating INS018_055 for Idiopathic ... - EurekAlert
Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the completion of patient enrollment in a Phase IIa study (NCT05938920) in China, which is investigating the safety, tolerability, and preliminary efficacy of INS018_055 for idiopathic Pulmonary Fibrosis (IPF).
None
Or read this on Eureka Alert